CL2022001886A1 - Anticuerpos anti-trem2 y métodos para utilizarlos - Google Patents
Anticuerpos anti-trem2 y métodos para utilizarlosInfo
- Publication number
- CL2022001886A1 CL2022001886A1 CL2022001886A CL2022001886A CL2022001886A1 CL 2022001886 A1 CL2022001886 A1 CL 2022001886A1 CL 2022001886 A CL2022001886 A CL 2022001886A CL 2022001886 A CL2022001886 A CL 2022001886A CL 2022001886 A1 CL2022001886 A1 CL 2022001886A1
- Authority
- CL
- Chile
- Prior art keywords
- trem2
- methods
- trem2 antibodies
- antibodies
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960663P | 2020-01-13 | 2020-01-13 | |
| US202063070728P | 2020-08-26 | 2020-08-26 | |
| US202063091717P | 2020-10-14 | 2020-10-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001886A1 true CL2022001886A1 (es) | 2023-03-24 |
Family
ID=74587108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001886A CL2022001886A1 (es) | 2020-01-13 | 2022-07-12 | Anticuerpos anti-trem2 y métodos para utilizarlos |
Country Status (4)
| Country | Link |
|---|---|
| CL (1) | CL2022001886A1 (fr) |
| EC (1) | ECSP22054464A (fr) |
| TW (1) | TW202128771A (fr) |
| WO (1) | WO2021146256A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302029A (en) | 2020-10-14 | 2023-06-01 | Denali Therapeutics Inc | Fusion proteins containing sulfoglucosamine sulfohydrolase enzymes and methods thereof |
| WO2023164516A1 (fr) | 2022-02-23 | 2023-08-31 | Alector Llc | Méthodes d'utilisation d'anticorps anti-trem2 |
| WO2023192282A1 (fr) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Méthodes de traitement de l'hypométabolisme du glucose cérébral |
| WO2023192288A1 (fr) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Molécules de liaison anti-trem2 monovalentes et leurs procédés d'utilisation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10087408B2 (en) | 2010-07-07 | 2018-10-02 | The University Of British Columbia | System and method for microfluidic cell culture |
| US9188593B2 (en) | 2010-07-16 | 2015-11-17 | The University Of British Columbia | Methods for assaying cellular binding interactions |
| JP2018537956A (ja) * | 2015-10-06 | 2018-12-27 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| WO2018152326A1 (fr) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Polypeptides de liaison au récepteur de transferrine modifiés |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| PT3601358T (pt) | 2017-08-03 | 2023-08-30 | Alector Llc | Anticorpos anti-trem2 e métodos de uso dos mesmos |
| EP3681909A1 (fr) * | 2017-09-14 | 2020-07-22 | Denali Therapeutics Inc. | Anticorps anti-trem2 et leurs procédés d'utilisation |
| CA3120970A1 (fr) | 2018-11-26 | 2020-06-04 | Denali Therapeutics Inc. | Procedes de traitement du metabolisme lipidique deregule |
-
2021
- 2021-01-13 TW TW110101213A patent/TW202128771A/zh unknown
- 2021-01-13 WO PCT/US2021/013200 patent/WO2021146256A1/fr active Application Filing
-
2022
- 2022-07-12 CL CL2022001886A patent/CL2022001886A1/es unknown
- 2022-07-12 EC ECSENADI202254464A patent/ECSP22054464A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP22054464A (es) | 2022-08-31 |
| TW202128771A (zh) | 2021-08-01 |
| WO2021146256A1 (fr) | 2021-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022009744A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CL2022001886A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CO2021012230A2 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos | |
| CO2021006911A2 (es) | Anticuerpos biespecíficos anti-pd-l1/anti-4-1bb y usos de los mismos | |
| CL2008003779A1 (es) | Anticuerpo bivalente bioespecifico que consta de las cadenas ligeras y pesadas de anticuerpos que se une a un primer y segundo antigeno, en el que los dominios constantes cl y ch1 y variables vl y vh, de las cadenas del anticuerpo para el segundo antigeno, se reemplazan entre si; metodo de producción; composición farmaceutica. | |
| UY32812A (es) | Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana. | |
| CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
| AR069775A1 (es) | Anticuerpos bivalentes biespecificos | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| CL2023001377A1 (es) | Anticuerpos anti-npr1 y usos de los mismos | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| AR118510A1 (es) | Métodos para la producción de células car-nk y sus usos | |
| EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
| ECSP21090414A (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| CO2022017348A2 (es) | Anticuerpos anti-tigit | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| AR122111A1 (es) | ANTICUERPOS CONTRA EL SARS-CoV-2 Y MÉTODOS DE SELECCIÓN Y USO DE LOS MISMOS | |
| AR116048A1 (es) | Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión | |
| ZA202205927B (en) | Anti-yellow fever virus antibodies, and methods of their generation and use | |
| CL2020000734A1 (es) | Expansión y uso de fracciones de células nk ampliadas. | |
| UY39089A (es) | Formulaciones de anticuerpos anti-tslp humanos y métodos de uso de los mismos | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| AR084263A1 (es) | Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen) | |
| AR122658A1 (es) | Anticuerpos que se unen a cd3 | |
| CO2023009279A2 (es) | Moléculas de unión a gucy2c y sus usos |